On June 8, 2025, Jami Ruben resigned from Relay Therapeutics' Board and Audit Committee, while Claire Mazumdar was appointed as a new Board member and Audit Committee chair on June 9, 2025, receiving 421,241 stock options at $3.36 each. This is part of the company's management changes and not due to any disputes.